ACRES Opens New Branch in Japan
The Alliance for Clinical Research Excellence and Safety (ACRES) has opened its first national affiliate, ACRES Japan, in Tokyo. Fumimaro Takaku, M.D., president of the Japanese Association of Medical Sciences, will act as president of the board of directors, and ACRES Japan will provide a model for the organization?s planned network of national affiliates.
The Alliance for Clinical Research Excellence and Safety (ACRES) has opened its first national affiliate, ACRES Japan, in Tokyo. Fumimaro Takaku, M.D., president of the Japanese Association of Medical Sciences, will act as president of the board of directors, and ACRES Japan will provide a model for the organization’s planned network of national affiliates.
ACRES Japan aims to develop high-quality clinical research both within Japan and worldwide by promoting education and training of investigators and study team members, supporting site accreditation, and developing an IT platform for effective information sharing.
"Clinical research must be conducted with high transparency; education and training of physician investigators for clinical research must be rigorous; a code of conduct for physicians collaborating with pharmaceutical companies for clinical search must be assured--addressing these concerns will lead to highest quality and efficiency of clinical research in Japan,” noted Takaku. “Through ACRES Japan, we are committed to finding effective solutions to these challenges.”
The executive officers are Kyoko Imamura, Ichiro Uchida, Kishio Ono, and Yasushi Suzuki. Planned activities range from advocating collaboration among like-minded organizations and individuals across Japan to participating in working groups of ACRES global initiatives and developing clinical research infrastructure in Japan. It will also create mechanisms to facilitate communication and collaboration between ACRES and local academic institutions, regulatory agencies, health systems, professional associations and patient organizations and to identify opportunities to further leverage ACRES-related Initiatives in Japan.
According to ACRES President Greg Koski, “This is a remarkable accomplishment by any measure. Organizations across the Japanese clinical research endeavor have shown extraordinary leadership, uniting to build a collaborative framework and expectation for excellence, one that will set very high standards and clear pathways for other nations seeking to achieve these goals. We look forward to our work together, not only with Japan, but with other countries worldwide.”
For the full press release, click here.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
